ScholarLens Back to search
2018•Journal of Stroke MedicineRequires access

Successful Treatment of Refractory Takayasu Arteritis with Tocilizumab—A Case Report

Nambiar Vivek K., T S Dhanya, Ajai Amrutha V.

Open publisher page 0 citations

Abstract

Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor.

About this research paper

What this paper is about

Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor.

Key concepts: Tocilizumab, Refractory (planetary science), Takayasu arteritis, Medicine, Vasculitis, Monoclonal, Takayasu's arteritis, Arteritis

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Successful Treatment of Refractory Takayasu Arteritis with Tocilizumab—A Case Report — Research Paper | ScholarLens